Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
Patient ate 15 minutes after taking the first dose of Vivoitf; Case reference number US-BN-2024-000199 is a spontaneous case report initially received from a pharmacist via Med Communication (reference number: USBAV24-0346) on 20-Feb-2024 and concerns a 64-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 18-Feb-2024, the patient took a first dose of Vivotif (batch number: unknown) at an unknown dose via oral route, for immunisation against disease caused by salmonella typhi. As reported, the patient ate 15 minutes after taking the dose (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A 64-year-old male patient took the first dose of Vivotif for immunisation against disease caused by salmonella typhi. As reported, the patient ate 15 minutes after taking the dose, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 64-year-old male patient took the first dose of Vivotif for immunisation against disease caused by salmonella typhi. As reported, the patient ate 15 minutes after taking the dose, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.